Last checked at 28 Feb 2023 15:55
28 February 2023
Destiny Pharma plc
Posting of Circular and Notice of General Meeting
Destiny Pharma plc (AIM: DEST) (the "Company" or "Destiny Pharma"), is pleased to confirm that, further to the announcement of 24 February 2023, the shareholder circular (the "Circular") providing further details of the Placing, Subscription and the Open Offer and notice of General Meeting has been posted to shareholders today.
The Circular contains a Notice of General Meeting to be held at the offices of Covington & Burling LLP, 22 Bishopsgate, London, EC2N 4BQ on 16 March 2023 at 2.00 p.m. (the "General Meeting"). Please note that the time of the General Meeting has changed from that announced on 24 February 2023.
A copy of the Circular, Open Offer Application Form and Form of Proxy will shortly be available from the Company's website (www.destinypharma.com).
Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the Circular.
EXPECTED TIMETABLE OF PRINCIPAL EVENTS
2023 | |||
Announcement of the Placing, the Open Offer and the Subscription | 24 February | ||
Record Date for entitlements under the Open Offer | Close of business on 23 February | ||
Ex-entitlement Date for the Open Offer | 8.00 a.m. on 27 February | ||
Posting of the Circular (including the Notice of General Meeting), the Form of Proxy and, to Qualifying Non-CREST Shareholders, the Application Form | 28 February | ||
Basic Entitlements and Excess Entitlements credited to stock accounts of Qualifying CREST Shareholders | As soon as possible on 1 March | ||
First Admission and commencement of dealings in the Placing Shares and the Subscription Shares on AIM | 8.00 a.m. on 1 March | ||
First Placing Shares in uncertificated form pursuant to First Admission expected to be credited to accounts in CREST | As soon as possible after 8.00 a.m. on 1 March | ||
Recommended latest time and date for requesting withdrawal of Basic Entitlements and Excess Entitlements from CREST | 4.30 p.m. on 9 March | ||
Latest time and date for depositing Basic Entitlements and Excess Entitlements into CREST | 3.00 p.m. on 10 March | ||
Latest time and date for splitting Application Forms (to satisfy bona fide market claims only) | 3.00 p.m. on 13 March | ||
Latest time and date for receipt of completed Application Forms and payment in full under the Open Offer or settlement of relevant CREST instructions (as appropriate) | 11.00 a.m. on 15 March | ||
Announcement of the results of the Open Offer | 15 March | ||
Latest time and date for receipt of CREST proxy instructions and registration of online votes from Shareholders for General Meeting | 2.00 p.m. on 14 March | ||
Latest time and date for receipt of Forms of Proxy | 2.00 p.m. on 14 March | ||
General Meeting | 2.00 p.m. on 16 March | ||
Announcement of the results of the General Meeting | 16 March | ||
Second Admission and commencement of dealings in the Committed Open Offer Shares on AIM | 8.00 a.m. on 17 March | ||
Committed Open Offer Shares in uncertificated form pursuant to Second Admission expected to be credited to accounts in CREST (uncertificated holders only) | As soon as possible after 8.00 a.m. on 17 March | ||
Dispatch of definitive share certificates for the New Shares in certificated form | Within 5 business days ofFirst Admission, or Second Admission, where applicable | ||
Each of the times and dates above refer to London time and are subject to change at the absolute discretion of the Company, finnCap and Shore Capital. Any such change will be notified to Shareholders by an announcement through a Regulatory Information Service. Certain of the events in the above timetable are conditional upon, inter alia, the approval of the Resolutions to be proposed at the General Meeting.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0)20 7220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
Optimum Strategic Communications
Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper
+44 (0) 203 922 0891
DestinyPharma@optimumcomms.com
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
Stern IR - US
Janhavi Mohite
+1-212-362-1200
Janhavi.Mohite@sternir.com